VectivBio (NASDAQ:VECT) Upgraded by Zacks Investment Research to Hold

VectivBio (NASDAQ:VECTGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need. VectivBio Holding AG is based in BASEL, Switzerland. “

Shares of VECT stock traded up $0.48 during midday trading on Wednesday, reaching $6.50. 305 shares of the company were exchanged, compared to its average volume of 16,705. VectivBio has a 12 month low of $2.74 and a 12 month high of $16.75. The company’s 50 day moving average price is $5.13 and its two-hundred day moving average price is $4.90.

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN acquired a new position in VectivBio during the 2nd quarter valued at $43,000. Geode Capital Management LLC grew its holdings in shares of VectivBio by 29.7% in the 4th quarter. Geode Capital Management LLC now owns 23,054 shares of the company’s stock worth $113,000 after purchasing an additional 5,274 shares during the last quarter. Canaan Partners XI LLC bought a new stake in shares of VectivBio in the 4th quarter worth about $182,000. Bank of America Corp DE grew its holdings in shares of VectivBio by 10,635.9% in the 4th quarter. Bank of America Corp DE now owns 72,682 shares of the company’s stock worth $357,000 after purchasing an additional 72,005 shares during the last quarter. Finally, CHI Advisors LLC grew its holdings in VectivBio by 0.3% during the 3rd quarter. CHI Advisors LLC now owns 2,592,602 shares of the company’s stock worth $20,028,000 after acquiring an additional 6,616 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

VectivBio Company Profile (Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy.

See Also

Get a free copy of the Zacks research report on VectivBio (VECT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VectivBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VectivBio and related companies with MarketBeat.com's FREE daily email newsletter.